NE BUSINESS BUREAU
AHMEDABAD, JULY 26
Mylan, a global pharmaceutical company, announced the commercial launch of its Remdesivir under the brand name Desrem in India to address urgent, unmet needs amid the evolving coronavirus 2019 (COVID-19) pandemic. The drug is approved for the treatment of suspected or laboratory confirmed incidences of COVID-19 in adults and children hospitalized with severe presentations of the disease, a company release said.
The company also launched a 24/7 helpline where patients and healthcare practitioners can access information about Mylan’s Remdesivir and its availability.
President, India and Emerging Markets, Rakesh Bamzai said: “In the wake of increasing cases of COVID-19 across India, Mylan remains committed to continue its efforts in the fight against the pandemic. With the launch of Desrem and our national 24/7 COVID-19 helpline, we aim to enhance access to this critical medicine, used for treating adults and children with severe presentations of Covid-19. At Mylan, we believe we have a responsibility to help make the world a better place, and the entire team at Mylan has stepped up in this time of need to serve patients and deliver better health for a better world.”
Mylan released the first batch of its generic Remdesivir Desrem and will continue to increase its supply across the country in the wake of the rising demand for the drug. Patients and healthcare practitioners can access information about the availability of Desrem in India through Mylan’s 24/7 national helpline number, +91.78299.80066.
Mylan will manufacture Desrem in its state-of-the-art injectable facility in Bangalore, which will work to service the demand in India and other export markets where Mylan has received a license from Gilead for the commercialization of Remdesivir. The previously announced agreement between Mylan and Gilead is part of a long-standing history between the two organizations to tackle key public health issues in India and around the world, beginning with expanding access to high quality, affordable HIV/AIDS antiretrovirals and now extending its partnership to include COVID-19 treatments.
